$142.18
Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Overview
52-week range
$20
$151
93% of range
Avg surprise (last 3)
+11.5%
Avg reaction (last 2)
-6.7%
0% positive
Latest IV / EM
71%
EM ±16.1% · $140 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-1.20 | $-0.90 | -33.3% | -62.2% | -13.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.03 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.86 | $-0.78 | -10.3% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.74 | $-3.40 | +78.2% | — | -0.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-3.94 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-2.47 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.54 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-8.70 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $3.62 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | -$1.16 | -$0.86 | -34.9% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-15M | — | $-10M | $-9M | $-8M | — | $-5M | $-3M |
| Net income | $-16M | — | $-11M | $-9M | $-8M | — | $-7M | $-4M |
| EPS (diluted) | $-1.20 | — | $-1.03 | $-0.86 | $-0.74 | — | $-3.94 | $-2.47 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $206M | $58M | $64M | $70M | $76M | $84M | $19M | $20M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $263M | $59M | $67M | $74M | $79M | $88M | — | — |
| Total assets | $264M | $60M | $67M | $74M | $79M | $88M | $21M | $25M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $31M | $32M | $28M | $26M | $24M | $26M | — | — |
| Total equity | $232M | $28M | $39M | $48M | $56M | $63M | $-87M | $-81M |